Bringing unmatched commerical experience and world-renowned science to the vital field of protein modulation.

BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs. The team’s core expertise is to discover and develop molecules that regulate protein homeostasis and stimulate the immune system to destroy cancers with minimal toxicities by utilizing enhanced biology-driven models. As a result, these novel drug candidates have large therapeutic windows. When coupled with clinically proven translational therapeutics targeting cancer and immune dysregulation, our goal is a rapid delivery of new drugs to improve lives of patients in need.

“The platform discovered by BioTheryX is exciting and broad, and can be applied to any substrate at will. It opens a wide window to the development of novel therapeutic modalities to a broad array of diseases, including malignancies and neurodegenerative disorders. Therefore, we are excited to be part of this novel and promising emerging approach"
-Professor Aaron Ciechanover, Nobel Laureate in Chemistry (2004) for the Discovery of Ubiquitin Mediated Protein Degradation


September 8, 2016 - BioRap and BioTheryX Sign Strategic Collaborative Agreement for the Development of Novel Protein Degradation Compounds for the Treatment of Cancer and Immune Disorder

May 4, 2016 - Yissum and BioTheryX Sign Licensing Agreement for the Development of Next-Generation Protein Degradation and Immunomodulatory Treatment for Hematological Cancers

Get in touch